Duopharma Biotech BhdXKLS:7148 83 Days Payable is 69.14 as of Mar. 2026, which is 94% above its 10-year median of 35.68. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 52.66% on this metric.
Duopharma Biotech Bhd Days Payable Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Days Payable distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Duopharma Biotech Bhd's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Days Payable of 69.14 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Duopharma Biotech Bhd and its competitors. This is 94% above median its historical median of 35.68. Over the past decade, Duopharma Biotech Bhd's Days Payable has ranged from 28.18 to 94.61. According to the industry distribution chart, Duopharma Biotech Bhd ranks #436 out of 921 companies in the Drug Manufacturers industry, placing it in the top 47.3%.
Is Duopharma Biotech Bhd's Days Payable too high?
Duopharma Biotech Bhd's current Days Payable of 69.14 is 94% above median its 10-year median of 35.68. Over the past 10 years, this metric has ranged from a low of 28.18 to a high of 94.61. The Drug Manufacturers industry median Days Payable is 90.69. Duopharma Biotech Bhd's value of 69.14 is 23.8% below this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #436 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #436 out of 921 companies for Days Payable. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median Days Payable is 90.69. Duopharma Biotech Bhd's value of 69.14 is 23.8% below this benchmark. Historically, Duopharma Biotech Bhd's own Days Payable has ranged from 28.18 to 94.61 over the past decade. While the company's 10-year median is 35.68 vs. the industry median of 90.69, Duopharma Biotech Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Days Payable of 69.14 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Days Payable is 69.14, which is 94% above median its own 10-year median of 35.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.19 — trading 21.7% below its estimated fair value. The current Days Payable is 69.14, which is 94% above median its 10-year median of 35.68 and 23.8% below the Drug Manufacturers industry median of 90.69. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Days Payable is 69.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.19 is trading 21.7% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Days Payable: 69.14 (94% above median its 10-year median of 35.68)
GF Value™: RM1.52 vs. price of RM1.19 (21.7% below fair value)
Industry Position: 23.8% below the Drug Manufacturers median (#436 of 921)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
